Manufacturing · Japan · 11,322 Employees
Headquartered in Tokyo, Japan, Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products.
View Company Info for Free
Who is Eisai
Top Competitors of Eisai
Eisai Org Chart
Eisai Email Formats
Eisai uses at least 5 email formats with first_last (ex. ) being used of the time
|Eisai Email Formats||Percentage|
|first initials + middle initials + last||JLSmith@hhc.eisai.co.jp|
|first + last||JohnSmith@hhc.eisai.co.jp|
Get Verified Emails
Eisai Company Metrics
Jul 18, 2022
Dec 17, 2021
KAN Research Institute, Inc.
Apr 10, 2021
See More Acquisitions & Subsidiaries
Eisai Tech Stack
Eisai News & Media
- TOKYO, Nov 30, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co., Ltd., (Eisai Thailand) has made an agreement to collaborate with the Department of Medical Services (DMS), Ministry of Public Health (MOPH) of Thailand to further enhance the access to treatments for dementia including Alzheimer’s disease (AD) in Thailand. In Thailand, the number of people suffering from dementia is expected to increase significantly from
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual MeetingTOKYO, Nov 22, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will have a total of nine poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orland, Florida and virtually from December 1-5, 2023. Major presentations include the design and outcomes of a clinical research evaluating
- TOKYO and CAMBRIDGE, Mass., Nov 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline. The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCEINVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL IMPROVEMENT AT 18 MONTHS IN LOW-TAU SUBPOPULATION IN ADDITIONAL ANALYSIS OF CLARITY AD...
- Recognized in the Medical Care Category NUTLEY, N.J., and CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI® (lecanemab-irmb) as one of the Best Inventions of 2023 in the Medical Care category. LEQEMBI...
Frequently Asked Questions regarding Eisai
Headquartered in Tokyo, Japan, Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products....